Casdin Capital’s NeoGenomics NEO Stock Holding History

Casdin Capital’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-488,889	Closed	-$22.1M	–	57
2021 Q2	$22.1M	Buy	+488,889	New	+$21.7M	0.56%	34

Other funds holding NEO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Casdin Capital's NEO Position: Q3 2021 in Review

Casdin Capital sold out of NeoGenomics (NEO) in Q3 2021, closing a stake of 488,889 shares — an estimated $22.1M sold.

Casdin Capital first reported a position in NEO in Q2 2021 and held it in 1 quarter. The position peaked at $22.1M in Q2 2021. 324 funds tracked by Wall St. Rank hold NEO as of Q3 2021.

Casdin Capital reported no remaining NeoGenomics position as of Q3 2021 after selling out during the quarter.
Casdin Capital sold 488,889 NeoGenomics shares in Q3 2021, an estimated $22.1M.
Casdin Capital first reported a position in NeoGenomics in Q2 2021 and held it in 1 quarter.
Casdin Capital's NeoGenomics position peaked at $22.1M in Q2 2021.
324 funds tracked by Wall St. Rank held NeoGenomics as of Q3 2021.

Based on Casdin Capital's 13F filing for Q3 2021, filed 15 Nov 2021.